U.S. C

U.S. Department of State

OMB No. 1405-0113

EXPIRATION DATE: XX/XX/XXXX
ESTIMATED BURDEN: 15 MINUTES
(See Page 2 - Back of Form)

			TUB	ERCULOS	SIS WO	RKSŁ	HEE	T		TIMATED BURD ee Page 2 - Back	DEN: 15 MINUTES of Form)	
	Photo	Surnames			Given Name	es				Age		
	Birth Date (mm-dd-yyyy)		y)	Document Type Docum			nent Nu	umber	(Case or Alien Number		
		Mediated Immunity to Tube losis Technical Instructions,		l ired, perform one t	type only, and	d attach re	esults					
I	<u> </u>	ned, mark which test: uantiFERON		QuantiFERON (ind	icate optimal	density v	alue	T-Spo	ot (<i>indicate</i>	spot count fo	or each)	
		-Spot		Nil Control:				Nil	Control:			
Date	e drawn <i>(mm</i>	n-dd-yyyy)		Antigen1:								
	Positive			3 Antigen2:								
	Negative Indetermin	nate, Borderline, or Equivoca		Mitogen:								
		Indication (Mark all that app										
	Chest X-	Ray not indicated	☐ Kno	wn HIV infection apulmonary tubero	vulocie		Histor	ry of Tub	erculosis			
Ė	_	symptoms of tuberculosis	=	A positive	00000					Date Chest X-Ray Taken (mm-dd-yyyy)		
3. C	hest X-Ray	Findings (for radiologist to	complete	all of Section 3)								
	Normal F			ndings (Indicate ca		inding, ma						
	1	Suggests Tuberculosis (I)					mears and C		
F	=	or consolidation	=	Miliary findings	_:			Class E		Not Mark a her on DS-2		
F	Cavitary	markings suggestive of fibro	=	viscrete linear opac viscrete nodule(s) v	-	_	_	rdiac			hickening (if at CPA,	
F) or mass with poorly defined	=	olume loss or retra			=	ruiac sculoske	ା୴	must confirm is n	ot effusion [do lateral ograph or ultrasound])	
_	•	(such as tuberculoma)	=	regular thick pleur			=	ner, spec	ify in	Diaphragmatic te	enting	
	Pleural e		=	Other	arreaction	-	_	marks	·	Single or scattere nodule(s)	ed calcified pulmonary	
	Hilar/med	diastinal adenopathy								Calcified lymph r	node(s)	
Rad	iologist's Re	emarks										
	F	Radiologist's Name (Printed)		Radio	logist's Signa	ture (Req	quired)		Date Ir	terpreted (m	ım-dd-yyyy)	
4. S	putum Sme	ears and Cultures Decisions	<u> </u>									
	No, not ir	ndicated -Applicant has no sig	gns or sym	ptoms of TB, no k	nown HIV inf	ection, an	nd:					
	X-ray	/ Normal or 'No specimens re	quired' an	d test for cell-medi	ated immuni	ty to TB n	egative	e (if perf	ormed)			
	X-ray	Normal or 'No specimens re	quired' an	d test for cell-medi	ated immuni	ty to TB p	ositive	(if perfo	rmed)			
Г	1 Vas ara	indicated - Applicant has (Ma	ark all that	annly):								
_		s or symptoms of TB	in an inai	пропу).	Extrapulmo	onary TB						
	=	st X-ray suggests TB		H	End of trea	-	ltures					
	=	vn HIV Infection										
5. S	putum Sme	ears and Cultures Results										
										7		
	Sputum	Date specimen obtained (mm-dd-yyyy)	Dat	e smear result rep (mm-dd-yyyy)	orted		P	ositive	Negative			
	Sputum Smear	1.		(30))))						1		
	Results	2.								1		
		3.								+		
		Date specimen obtained		culture result repo			P	ositive	Negative	NTM	Contaminated	
	Sputum Culture	(<i>mm-dd-yyyy</i>)	USE ITIOS	t recent date as da	ale oi exam d	טב-205 ווי)4					
	Results						+					
		2.					+					

Ap	perculosis Classification plicants can be both Class B1 and Class B3, or Class B2 and Class B3. However, other combinations of tuberculosis classifications are not rmitted.
	No TB Classification CXR not suggestive of tuberculosis, no tuberculosis signs or symptoms, no known HIV infection, TST or IGRA negative (if performed), not a contact
	Class A Applicant has tuberculosis disease
	Class B0, TB, Pulmonary Diagnosed with tuberculosis by the panel physician or presented to the panel physician while on tuberculosis treatment and successfully completed DGMQ-defined DOT
	Class B1 TB, Pulmonary CXR suggests tuberculosis, or tuberculosis signs and symptoms, or known HIV infection and sputum smears and cultures are negative and not a clinically diagnosed case.
	Class B1 TB, Extrapulmonary Applicants with evidence of extrapulmonary tuberculosis. The anatomic site of infection should be documented.
	Anatomic Site of Disease No treatment
	Class B2 TB, LTBI Evaluation Applicants who have a tuberculin skin test ≥10 mm or positive IGRA but otherwise have a negative evaluation for tuberculosis. Contacts with TST ≥ 5 mm or positive IGRA should receive this classification (if they are not already Class B1 TB, Pulmonary).
	No LTBI treatment Current LTBI treatment Completed LTBI treatment Completed LTBI treatment Dates of treatment Dates of treatment If treated, mark LTBI regimen: If treated, mark LTBI regimen: Isoniazid Rifampin 3HP Other
	Class B3 TB, Contact Evaluation Applicants who are a recent contact of a known tuberculosis case.
	No preventive treatment Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to
	☐ Window Prophylaxis
	☐ Window Prophylaxis ☐ Isoniazid ☐ Rifampin ☐ 3HP ☐ Other Dates of treatment to
	Window Prophylaxis ☐ Isoniazid ☐ Rifampin ☐ 3HP ☐ Other Dates of treatment to
	Window Prophylaxis □ Isoniazid □ Rifampin □ 3HP □ Other
	Window Prophylaxis Isoniazid Rifampin Other Dates of treatment to Source Case: Name Case or Alien Number, if known
	Window Prophylaxis Isoniazid Rifampin Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact
Rema	Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact Date Contact Ended (mm-dd-yyyy) Case of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available
Rema	Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact Date Contact Ended (mm-dd-yyyy) Case of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available
Rema	Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact Date Contact Ended (mm-dd-yyyy) Case of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available
Rema	Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact Date Contact Ended (mm-dd-yyyy) Case of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available
Rema	Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact Date Contact Ended (mm-dd-yyyy) Case of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available
Rema	Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to Source Case: Name Case or Alien Number, if known Relationship to Contact Date Contact Ended (mm-dd-yyyy) Case of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available

DS-3030 Page 2 of 4

		outmont a	t the time of presentation	i for their me	edicai examinatio	on		
was the diagr	nosis made: F	ositive la	boratory tests	Clinical di	agnosis			
agnostic Ches	t Radiograph							
Facility perfo	rming chest radiog	raph:				-		
Date Radiog	raph obtained (mm	-dd-yyyy)):					
ndings Presen	t							
■ Normal	or no findings sugg	gestive of	tuberculosis		Hilar/mediastina	l adenopat	hy	
Infiltrate	e or consolidation				Miliary findings			
Reticula	ar marking suggesti	ve of fibr	osis	$\overline{\Box}$	Discrete linear of	pacity		
Cavitar				=	Discrete nodule		calcification	
_			ad manusina (avala aa	님			Calcinication	
tubercu		oriy delin	ed margins (such as	님	Volume loss or			
	effusion			ᆜ	Irregular thick pl	eural reacti	ion	
					Other			
outum Smear F	Result at Diagnosis							
Date speci	men obtained	[Date results reported	Pocitio	vo Nogotivo			
(mm-	dd-yyyy)		(mm-dd-yyyy)	Positiv	ve Negative			
outum Culturo	Pocult at Diagnosis							
	Result at Diagnosis		Date results reported					
	Date specimen obtained (mm-dd-yyyy)		(mm-dd-yyyy)		ve Negative	NTM	Contami	nated
ug Susceptibil	ity Test Results							
M	ethod of DST:		Date specimen ob			DST reported		
	-		(mm-dd-yyy)	<u>/) </u>	(11111	i-aa-yyyy)		
MGIT	Agar L	.J						
	1	Drug			Susceptible	Res	sistant	
December 14	Isoniazid							
Required for first-line DST	Rifampin Ethambutol							
50 10	Pyrazinamide							
	Ethionamide							
Required for	Amikacin							
multidrug-	Capreomycin							
resistant	Para-aminosalicy	lic acid (I	PAS)					
cases	Fluoroquinolone,	specify:						
	Other enceifur				I			
	Other, specify:							
	Other, specify:							
	Other, specify:							
	Other, specify:							

DS-3030 Page 3 of 4

listory of Class A TB, Continu	ed							
Vere molecular tests used in add	dition to the	required s	sputum sm	nears, cultu	ıres, and Γ	DST:		
No								
Yes (mark all that apply):								
	Mycobacterium Tuberculosis		Rifampin Resistance		Isoniazid Resistance			
Molecular Test	Positive	Negative	Positive	Negative	Positive	Negative		
Hain Line Probe Assay								Performed, attach results
GeneXpert								Performed, attach results
Other_								Performed, attach results
Treating physician or institution Approved DOT site: Unapproved TB treatment								
Drug	Dosa	ıge			Start Date	e (mm-dd-y	уууу)	End Date (mm-dd-yyyy)
Isoniazid								
Rifampin								
Ethambutol					ļ			
Pyrazinamide					ļ			
Other, specify:					 			
						-		

PAPERWORK REDUCTION ACT AND CONFIDENTIALITY STATEMENTS

PAPERWORK REDUCTION ACT STATEMENT

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including time required for searching existing data sources, gathering the necessary documentation, providing the information and/or documents required, and reviewing the final collection. You do not have to supply this information unless this collection displays a currently valid OMB control number. If you have comments on the accuracy of this burden estimate and/or recommendations for reducing it, please send them to: PRA BurdenComments@state.gov

CONFIDENTIALITY STATEMENT

INA Section 222(f) provides that visa issuance and refusal records shall be considered confidential and shall be used only for the formulation, amendment, administration, or enforcement of the immigration, nationality, and other laws of the United States. The U.S. Department of State uses the information provided on this form to determine an individual's eligibility for a U.S. visa. Certified copies of visa records may be made available to a court which certifies that the information contained in such records is needed in a case pending before the court. The information provided may also be released to federal agencies for law enforcement, counterterrorism and homeland security purposes; to Congress and courts within their sphere of jurisdiction; and to other federal agencies who may need the information to administer or enforce U.S. laws. Although furnishing this information is voluntary, individuals who fail to submit this form or who do not provide all the requested information may be denied a U.S. visa or experience processing delays.

DS-3030 Page 4 of 4